Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units".
NCT06159894 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90
Last updated 2026-02-20
Summary
This is a clinical trial whose main purpose is to evaluate the acceptability of the administration of LA CAB + extended-release RPV as perceived by patients in month 12 in multipurpose day hospital units versus specialized care centers (HIV Units). . Candidates to participate in this study are indicated to receive this medication, so the decision to include the participant in the study will be after the decision to prescribe the drug. These patients will be randomly assigned to one location or another to receive the administration of the medication. Therefore, and after consulting with the AEMPS, it is considered that this is a clinical trial WITHOUT medications. Both the medication and the procedures associated with the follow-up of the participants will follow the usual practice for this type of patient, with the exception of completing the questionnaires aimed at evaluating the primary and secondary objectives of this study.
Conditions
- HIV Infections
Interventions
- OTHER
-
DAY HOSPITAL ARM
The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms. The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored. Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice.
- OTHER
-
Specialist-Care arm
The study will evaluate the feasibility and acceptability of the administration of CAB LA + RPV LA as perceived by patients. The focus will be upon both Polyvalent Day Hospital units vs Specialist-Care centers. The evaluations of the two-implementation strategies and their differences will be assessed in essentially descriptive terms. The study will also explore the fidelity, uptake and costs of LA CAB + RPV administration upon both Polyvalent Day Hospital units vs Specialist-Care Centers. The utility of the implementation strategies devised to support the delivery LA CAB + RPV out of HIV units/Internal medicine services will also be explored. Finally, the study will assess the safety, tolerability and effectiveness LA CAB + RPV administration in Polyvalent Day Hospital units vs Specialist-Care centers in the total sample, as per clinical practice.
Sponsors & Collaborators
-
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-12-18
- Primary Completion
- 2025-04-21
- Completion
- 2026-02-18
Countries
- Spain
Study Locations
More Related Trials
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805 ·Status: RECRUITING ·Phase: PHASE3
-
Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.
NCT06646562 ·Status: RECRUITING ·Phase: PHASE4
-
Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)
NCT04001803 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05917509 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
NCT05660980 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Patient-Reported Outcomes in Real-life of Cabotegravir and Rilpivirine
NCT06403865 ·Status: NOT_YET_RECRUITING
-
IMplementation of CAB+RPV LA for People With HIV in Non-Metropolitan Areas
NCT06451341 ·Status: ACTIVE_NOT_RECRUITING
-
Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine
NCT05835635 ·Status: NOT_YET_RECRUITING
-
Clinical Effectiveness-Implementation Hybrid Type 2 Study on Home-Delivered Cabenuva for People Living With HIV Who Are Not Retained in Care
NCT06062979 ·Status: ENROLLING_BY_INVITATION
-
CAbotégravir LENacapavir DUal Long Acting
NCT06657885 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study
NCT03639311 ·Status: COMPLETED ·Phase: PHASE2
-
Satisfaction of HIV-infected Patients Treated With Cabotegravir-rilpivirine Injectable Dual Therapy
NCT05697289 ·Status: UNKNOWN
-
A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA
NCT05601128 ·Status: COMPLETED ·Phase: PHASE3
-
Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
NCT06273943 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
NCT01363011 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
NCT01533259 ·Status: COMPLETED ·Phase: PHASE3
-
EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS
NCT03683524 ·Status: COMPLETED ·Phase: PHASE4
-
Administration of High Doses of Antiretroviral Drugs to Eliminate the Latent HIV-1 Reservoir
NCT06640192 ·Status: RECRUITING ·Phase: PHASE2
-
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
NCT05349838 ·Status: COMPLETED ·Phase: PHASE3
-
REal-Life Cohort With DOlutegravir + LAmivudina
NCT04638686 ·Status: COMPLETED
-
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
NCT01475838 ·Status: COMPLETED ·Phase: PHASE3
-
Post-Injectable Cabotegravir Antiretroviral Salvage Strategy Options Trial
NCT06485154 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
NCT05300035 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
NCT04150068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01440569 ·Status: COMPLETED ·Phase: PHASE3